Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'fluvastatin' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 193 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Orietta Zaniolo; Mario Eandi
      Profilo terapeutico e farmacoeconomico della formulazione a rilascio prolungato (RP) di fluvastatina

      Farmeconomia e percorsi terapeutici
    2. Lanchote, VL; Rocha, A; de Albuquerque, FUV; Coelho, EB; Bonato, PS
      Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies

      JOURNAL OF CHROMATOGRAPHY B
    3. Nakashima, A; Saxer, C; Niina, M; Masuda, N; Iwasaki, K; Furukawa, K
      Determination of fluvastatin and its five metabolites in human plasma using simple gradient reversed-phase high-performance liquid chromatography with ultraviolet detection

      JOURNAL OF CHROMATOGRAPHY B
    4. Maclaine, GDH; Patel, H
      A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    5. Holdaas, H; Fellstrom, B; Holme, I; Nyberg, G; Fauchald, P; Jardine, A; Gronhagen-Riska, C; Madser, S; Neumayer, HH; Cole, E; Maes, B; Weinreich, T; Olsson, AG; Pedersen, TR; Benghozi, R; Hartmann, A
      Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol (R) in Renal Transplantation) study design and baseline data

      JOURNAL OF CARDIOVASCULAR RISK
    6. Woodfield, A
      Augmenting reference pricing of pharmaceuticals in New Zealand with strategic cross-product agreements

      PHARMACOECONOMICS
    7. Yasunari, K; Maeda, K; Minami, M; Yoshikawa, J
      HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress

      ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    8. Kagawa, H; Nomura, S; Nagahama, M; Ozaki, Y; Fukuhara, S
      Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia

      CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
    9. Mueck, AO; Seeger, H; Deuringer, FU; Wallwiener, D
      Effect of an estrogen/statin combination on biochemical markers of endothelial function in human coronary artery cell cultures

      MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
    10. Imaeda, A; Aoki, T; Kondo, Y; Hori, M; Ogata, M; Obayashi, H; Hasegawa, G; Nakamura, N; Tokuda, K; Nishino, H; Yoshikawa, T; Kondo, M
      Protective effects of fluvastatin against reactive oxygen species induced DNA damage and mutagenesis

      FREE RADICAL RESEARCH
    11. Song, JC; White, CM
      Do HMG-CoA reductase inhibitors affect fibrinogen?

      ANNALS OF PHARMACOTHERAPY
    12. Mueck, AO; Seeger, H; Wallwiener, D
      Further evidence for direct vascular actions of statins: Effect on endothelial nitric oxide synthase and adhesion molecules

      EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    13. Bjarnason, NH; Riis, BJ; Christiansen, C
      The effect of fluvastatin on parameters of bone remodeling

      OSTEOPOROSIS INTERNATIONAL
    14. Obata, T; Ebihara, A; Yamanaka, Y
      Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzymeA reductase, on nitric oxide-induced hydroxyl radical generation in the rat heart

      BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
    15. Steiner, S; Gatlin, CL; Lennon, JJ; McGrath, AM; Seonarain, MD; Makusky, AJ; Aponte, AM; Esquer-Blasco, R; Anderson, NL
      Cholesterol biosynthesis regulation and protein changes in rat liver following treatment with fluvastatin

      TOXICOLOGY LETTERS
    16. Kolovou, G
      The treatment of coronary heart disease: An update - Part 3: Statins beyond cholesterol lowering

      CURRENT MEDICAL RESEARCH AND OPINION
    17. Illingworth, RD; Crouse, JR; Hunninghake, DB; Davidson, MH; Escobar, ID; Stalenhoef, AFH; Paragh, G; Ma, PTS; Liu, M; Melino, MR; O'Grady, L; Mercuri, M; Mitchel, YB
      A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial

      CURRENT MEDICAL RESEARCH AND OPINION
    18. Wierzbicki, AS
      Synthetic statins: More data on newer lipid-lowering agents

      CURRENT MEDICAL RESEARCH AND OPINION
    19. Hilleman, DE; Monaghan, MS; Ashby, CL; Mashni, JE; Woolley, K; Amato, CM
      Physician-prompting statin therapy intervention improves outcomes in patients with coronary heart disease

      PHARMACOTHERAPY
    20. Langford, NJ; Kendall, MJ
      Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    21. Coelho, OR; De Luca, IMS; Tanus-Santos, JE; Cittadino, M; Sampaio, RC; Coelho, OR; Hyslop, S; Moreno, H
      Pravastatin reduces myocardial lesions induced by acute inhibition of nitric oxide biosynthesis in normocholesterolemic rats

      INTERNATIONAL JOURNAL OF CARDIOLOGY
    22. Isaacsohn, J; Insull, W; Stein, E; Kwiterovich, P; Ma, P; Brazg, R; Dujovne, CA; Shan, M; Shugrue-Crowley, E; Ripa, S; Tota, R
      Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia

      CLINICAL CARDIOLOGY
    23. Olsson, AG
      A new statin: A new standard

      CLINICAL CARDIOLOGY
    24. Brinton, EA
      Newer HMG-CoA reductase inhibitor (statin) therapies

      CLINICAL CARDIOLOGY
    25. Lopez, S; Peiretti, F; Bonardo, B; Deprez-Beauclair, P; Laouenan, H; Juhan-Vague, I; Nalbone, G
      Effect of atorvastatin on plasminogen activator inhibitor type-1 synthesisin human monocytes/macrophages

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    26. Sabia, H; Prasad, P; Smith, HT; Stoltz, RR; Rothenberg, P
      Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    27. van Dam, MJ; Penn, HJAM; den Hartog, FR; Kragten, HA; Trip, MD; Buirma, RJA; Kastelein, JJP
      A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: A randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease

      CLINICAL THERAPEUTICS
    28. Ballantyne, CM; Pazzucconi, F; Pinto, X; Reckless, JP; Stein, E; McKenney, J; Bortolini, M; Chiang, YT
      Efficacy and tolerability of fluvastatin extended-release delivery system:A pooled analysis

      CLINICAL THERAPEUTICS
    29. Olsson, AG; Pauciullo, P; Soska, V; Luley, C; Pieters, RE; Broda, G; Palacios, B
      Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: A randomized trial

      CLINICAL THERAPEUTICS
    30. Nakashima, A; Ohtawa, M; Masuda, N; Morikawa, H; Iwasaki, K
      Antioxidative effects of fluvastatin, and its major metabolites [II]

      YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
    31. Nakashima, A; Ohtawa, M; Iwasaki, K; Wada, M; Kuroda, N; Nakashima, K
      Inhibitory effects of fluvastain and its metabolites on the formation of several reactive oxygen species

      LIFE SCIENCES
    32. Lloyd, GW; Jackson, G; Foley, DP; Boersma, E; Shepherd, J; Serruys, PW
      The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty - Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial

      ATHEROSCLEROSIS
    33. Shiomi, M; Ito, T; Hirouchi, Y; Enomoto, M
      Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins

      ATHEROSCLEROSIS
    34. Sumi, D; Hayashi, T; Thakur, NK; Jayachandran, M; Asai, Y; Kano, H; Matsui, H; Iguchi, A
      A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects - the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action

      ATHEROSCLEROSIS
    35. Haak, E; Abletshauser, C; Weber, S; Goedicke, C; Martin, N; Hermanns, N; Lackner, K; Kusterer, K; Usadel, KH; Haak, T
      Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia

      ATHEROSCLEROSIS
    36. Ubels, FL; Muntinga, JHJ; van Doormaal, JJ; Reitsma, WD; Smit, AJ
      Effects of initial and long-term lipid-lowering therapy on vascular wall characteristics

      ATHEROSCLEROSIS
    37. Ozaki, K; Yamamato, T; Ishibashi, T; Matsubara, T; Nishio, M; Aizawa, Y
      Regulation of endothelial nitric oxide synthase and endothelin-1 expression by fluvastatin in human vascular endothelial cells

      JAPANESE JOURNAL OF PHARMACOLOGY
    38. Lutucuta, S; Ballantyne, CM; Elghannam, H; Gotto, AM; Marian, AJ
      Novel polymorphisms in promoter region of ATP binding cassette transportergene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy

      CIRCULATION RESEARCH
    39. Marz, W; Scharnagl, H; Abletshauser, C; Hoffmann, MM; Berg, A; Keul, J; Wieland, H; Baumstark, MW
      Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype

      CIRCULATION
    40. Lefer, AM; Scalia, R; Lefer, DJ
      Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease

      CARDIOVASCULAR RESEARCH
    41. Luo, JD; Xie, F; Zhang, WW; Ma, XD; Guan, JX; Chen, X
      Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes

      BRITISH JOURNAL OF PHARMACOLOGY
    42. Ray, JG; Mamdani, M; Tsuyuki, RT; Anderson, DR; Yeo, EL; Laupacis, A
      Use of statins and the subsequent development of deep vein thrombosis

      ARCHIVES OF INTERNAL MEDICINE
    43. Cromwell, W; Ziajka, P
      Tachyphylaxis in 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors - Reply

      AMERICAN JOURNAL OF CARDIOLOGY
    44. Jones, PH
      Tachyphylaxis in 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

      AMERICAN JOURNAL OF CARDIOLOGY
    45. Olsson, AG
      Statin therapy and reductions in low-density lipoprotein cholesterol: Initial clinical data on the potent new statin rosuvastatin

      AMERICAN JOURNAL OF CARDIOLOGY
    46. McPherson, R; Angus, C; Murray, P; Genest, A
      Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH)

      AMERICAN HEART JOURNAL
    47. Muls, E; De Backer, G; Brohet, C; Heller, F
      The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial

      ACTA CARDIOLOGICA
    48. Barter, PJ
      Treating to target with statins

      ATHEROSCLEROSIS SUPPLEMENTS
    49. Barter, P
      Cholesterol management: how to implement best practice

      EUROPEAN HEART JOURNAL SUPPLEMENTS
    50. Cowie, MR
      Statins: where are we now?

      HOSPITAL MEDICINE
    51. Romano, M; Mezzetti, A; Marulli, C; Ciabattoni, G; Febo, F; Di Ienno, S; Roccaforte, S; Vigneri, S; Nubile, G; Milani, M; Davi, G
      Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: Role of nitric oxide

      JOURNAL OF INVESTIGATIVE MEDICINE
    52. Lill, J; Bauer, LA; Horn, JR; Hansten, PD
      Cyclosporine-drug interactions and the influence of patient age

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    53. Mueck, AO; Seeger, H; Wallwiener, D
      Fluvastatin combined with 17 beta-estradiol: Effect on the oxidation of human low density lipoprotein

      EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    54. Elghannam, H; Tavackoli, S; Ferlic, L; Gotto, AM; Ballantyne, CM; Marian, AJ
      A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy

      JOURNAL OF MOLECULAR MEDICINE-JMM
    55. Seeger, H; Mueck, AO; Lippert, TH
      Fluvastatin increases prostacyclin and decreases endothelin production by human umbilical vein endothelial cells

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    56. Suzumura, K; Tanaka, K; Yasuhara, M; Narita, H
      Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    57. Yasuhara, M; Suzumura, K; Tanaka, K; Takahashi, M; Aoki, S; Odawara, A; Narita, H; Suzuki, T
      Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    58. Salazar, LA; Hirata, MH; Quintao, ECR; Hirata, RDC
      Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene inBrazilian patients with primary hypercholesterolemia

      JOURNAL OF CLINICAL LABORATORY ANALYSIS
    59. Ballantyne, CM; Herd, JA; Stein, EA; Ferlic, LL; Dunn, JK; Gotto, AM; Marian, AJ
      Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy

      JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
    60. Whitfield, LR; Stern, RH; Sedman, AJ; Abel, R; Gibson, DM
      Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase

      EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
    61. Ambrosi, P; Aillaud, MF; Habib, G; Kreitmann, B; Metras, D; Luccioni, R; Bouvenot, G; Juhan-Vague, I
      Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients

      THROMBOSIS AND HAEMOSTASIS
    62. Suzumura, K; Kasahara, E; Ohnishi, Y; Chien, KC; Inoue, M
      Fluvastatin normalizes the decreased turnovers of glutathione and ascorbicacid in watanabe heritable hyperlipidaemic rabbits

      CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
    63. Kagota, S; Yamaguchi, Y; Nakamura, K; Kunitomo, M
      Functional evidence for anti-oxidant action of fluvastatin on low-density lipoprotein using isolated macrophages and aorta

      CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
    64. Kurusu, A; Shou, I; Nakamura, S; Fukui, M; Shirato, I; Tomino, Y
      Effects of the new hydroxy-3-methylglutaryl coenzyme a reductase inhibitorfluvastatin on anti-oxidant enzyme activities and renal function in streptozotocin-induced diabetic rats

      CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
    65. Deskur-Smielecka, E; Wykretowicz, A; Banaszak, A; Szczepanik, A; Furmaniuk, J; Wysocki, H
      The influence of treatment of hypercholesterolemic patients with simvastatin on plasma chemotactic activity and adherence of neutrophils

      INTERNATIONAL JOURNAL OF CARDIOLOGY
    66. Eichstadt, HW; Abletshauser, CB; Stork, T; Weidinger, G
      Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    67. Spieker, LE; Noll, G; Hannak, M; Luscher, TF
      Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    68. Saitta, A; Castaldo, M; Sardo, A; Saitta, MN; Cinquegrani, M; Bonaiuto, M; D'Arrigo, P; Zema, M; Squadrito, F
      Effects of fluvastatin treatment on red blood cell Na+ transport systems in hypercholesterolemic subjects

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    69. Satoh, K; Ichihara, K
      Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    70. Bandoh, T; Mitani, H; Niihashi, M; Kusumi, Y; Kimura, M; Ishikawa, J; Totsuka, T; Sakurai, I; Hayashi, S
      Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    71. Cohen, LH; van Leeuwen, REW; van Thiel, GCF; van Pelt, JF; Yap, SH
      Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes

      BIOPHARMACEUTICS & DRUG DISPOSITION
    72. Kersting, F; Selenka, A; Walch, S
      Effects of cholestyramine on vitamin E levels in patients treated with statins

      JOURNAL OF CLINICAL PHARMACOLOGY
    73. Demetriou, D; Shabpar, A; Bohmig, G; Schmaldienst, S; Horl, WH; Watschinger, B
      Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation

      WIENER KLINISCHE WOCHENSCHRIFT
    74. Kantola, T; Backman, JT; Niemi, M; Kivisto, KT; Neuvonen, PJ
      Effect of fluconazole on plasma fluvastatin and pravastatin concentrations

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    75. Kozlov, SG; Lyakishev, AA; Tvorogova, MG
      Assessment of efficacy of fluvastatin and fenofibrate in patients with noninsulin-dependent diabetes with hypercholesterolemia and combined hyperlipidemia

      KARDIOLOGIYA
    76. Pauciullo, P; Borgnino, C; Paoletti, R; Mariani, M; Mancini, M
      Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

      ATHEROSCLEROSIS
    77. Kyrklund, C; Backman, JT; Kivisto, KT; Neuvonen, M; Laitila, J; Neuvonen, PJ
      Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    78. Cahilly, C; Ballantyne, CM; Lim, DS; Gotto, A; Marian, AJ
      A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis

      CIRCULATION RESEARCH
    79. Jones, PH
      The nature of the statins

      CIRCULATION
    80. Nakamura, T; Nishi, H; Kokusenya, Y; Hirota, K; Miura, Y
      Mechanism of antioxidative activity of fluvastatin-determination of the active position

      CHEMICAL & PHARMACEUTICAL BULLETIN
    81. Obata, T; Yamanaka, Y
      Protective effect of fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on MPP+-induced hydroxyl radical in the rat striatum

      BRAIN RESEARCH
    82. Mascaro, C; Ortiz, JA; Ramos, MM; Haro, D; Hegardt, FG
      Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase transcription

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    83. Kusus, M; Stapleton, DD; Lertora, JJL; Simon, EE; Dreisbach, AW
      Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions

      AMERICAN JOURNAL OF THE MEDICAL SCIENCES
    84. Wierzbicki, AS; Lumb, PJ; Chik, G; Crook, MA
      High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia

      AMERICAN JOURNAL OF CARDIOLOGY
    85. Brown, WV
      Cholesterol lowering in atherosclerosis

      AMERICAN JOURNAL OF CARDIOLOGY
    86. Safeer, RS; Lacivita, CL
      Choosing drug therapy for patients with hyperlipidemia

      AMERICAN FAMILY PHYSICIAN
    87. McVey, D; Patel, H; Eminton, Z; Maton, S
      An assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL-cholesterol goals: The atorvastatin matrix study

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    88. Neil, H; Fowler, G; Patel, H; Eminton, Z; Maton, S
      An assessment of the efficacy of atorvastatin in achieving LDL cholesteroltarget levels in patients with coronary heart disease: A general practice study

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    89. Elliott, WJ; Weir, DR
      Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    90. Moisan, J; Vaillancourt, E; Gregoire, JP; Gaudet, M; Cote, I; Leach, A
      Preferred hydroxymethylglutaryl-coenzyme A reductase inhibitors: Treatment-modification program and outcomes

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    91. Maltz, HC; Balog, DL; Cheigh, JS
      Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine

      ANNALS OF PHARMACOTHERAPY
    92. Gottsater, A; Anwaar, I; Lind, P; Mattiasson, I; Lindgarde, F
      Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclicnucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin

      BLOOD COAGULATION & FIBRINOLYSIS
    93. Czopf, L; Halmosi, R; Kesmarky, G; Habon, T; Toth, K; Juricskay, I; Roth, E; Mozsik, G
      Lovastatin and nitrate therapy induced changes in hemorheological parameters and in free radical mediated processes in patients with ischemic heart disease

      PERFUSION
    94. Marz, W; Wollschlager, H; Klein, G; Neiss, A; Wehling, M
      Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE Trial)

      PERFUSION
    95. Suzumura, K; Odawara, A; Yasuhara, M; Tanaka, K; Narita, H; Suzuki, T
      In vitro inhibitory effects of the optical isomers and metabolites of fluvastatin on copper ion-induced LDL oxidation

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    96. Bruckert, E; Simonetta, C; Giral, P
      Compliance with fluvastatin treatment characterization of the noncompliantpopulation within a population of 3845 patients with hyperlipidemia

      JOURNAL OF CLINICAL EPIDEMIOLOGY
    97. Lindahl, A; Persson, B; Ungell, AL; Lennernas, H
      Surface activity and concentration dependent intestinal permeability in the rat

      PHARMACEUTICAL RESEARCH
    98. Ohtawa, M; Masuda, N; Akasaka, I; Nakashima, A; Ochiai, K; Moriyasu, M
      Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    99. Rindone, JP
      The outcome of very low dosages of simvastatin in patients with hypercholesterolemia

      PHARMACOTHERAPY
    100. Seeger, H; Lippert, C; Wallwiener, D; Mueck, AO
      Fluvastatin combined with 17 beta-estradiol and norethisterone: effect on the proliferation of smooth muscle cells from human coronary artery

      MEDICAL SCIENCE RESEARCH


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/06/20 alle ore 21:08:59